TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Hansa Biopharma AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
171,316
|
134,094
|
154,525 |
| Financial expenses |
187,164
|
105,520
|
48,639 |
| Earnings before taxes |
-925,769
|
-830,812
|
-609,979 |
| EBITDA |
-621,752
|
-778,671
|
-588,588 |
| Total assets |
2,062,596
|
1,018,041
|
1,687,406 |
| Current assets |
563,838
|
855,151
|
1,604,704 |
| Current liabilities |
253,526
|
320,988
|
264,714 |
| Equity capital |
674,450
|
-167,876
|
602,911 |
| - share capital |
67,814
|
55,034
|
55,034 |
| Employees (average) |
0
|
159
|
144 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
32.7%
|
-16.5%
|
35.7% |
| Turnover per employee |
843
|
1,073 | |
| Profit as a percentage of turnover |
-540.4%
|
-619.6%
|
-394.7% |
| Return on assets (ROA) |
-35.8%
|
-71.2%
|
-33.3% |
| Current ratio |
222.4%
|
266.4%
|
606.2% |
| Return on equity (ROE) |
-137.3%
|
494.9%
|
-101.2% |
| Change turnover | |||
| Change turnover % |
-13%
|
356% | |
| Chg. No. of employees | |||
| Chg. No. of employees % |
10%
|
24% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.